AstraZeneca Q3 2026 reported EPS rises 23% to $2.02
AZN•AstraZeneca's Q3 2026 reported EPS rose 23% to $2.02, and total revenue increased 7% to $16.21 billion. The company targets $1.5 billion in annualized pretax restructuring benefits, with one-time costs of up to $2 billion.
1. Quarterly results and plans
AstraZeneca's Q3 2026 reported EPS rose 23% to $2.02, while total revenue increased 7% to $16.21 billion. Its restructuring program targets $1.5 billion in annualized pretax benefits and could involve one-time costs of up to $2 billion. CEO Pascal Soriot said 12 positive Phase III program readouts year-to-date have collective peak-year revenue potential exceeding $10 billion.
